Last reviewed · How we verify
A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer
Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally advanced pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy and radiation therapy with tipifarnib may be an effective treatment for pancreatic cancer.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 154 |
| Start date | 2001-11 |
Conditions
- Adenocarcinoma of the Pancreas
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
Interventions
- gemcitabine hydrochloride
- paclitaxel
- tipifarnib
- radiation therapy
Primary outcomes
- Overall survival — 1 year
Calculated along with associated 95% confidence intervals.
Countries
United States